ANAB (AnaptysBio Inc) Net Profit

ANAB (AnaptysBio) - company brandmark

AnaptysBio, Inc. (ANAB) is optimizing biomaterial supplies for testing by utilizing multiple contractors to protect margins. This chart's price indicator reflects profit dynamics, which currently stand at 0.19, while revenue relies on grants and licenses for antibody development. The strategy of transferring rights to industry behemoths at early stages allows the company to avoid price wars, ensuring a steady stream of milestone payments.

ANAB (AnaptysBio, Inc.) Net Profit history from 07/04/2022 to 10/29/2026

Analytical breakdowns and data insights for company AnaptysBio (ANAB)

- price and consensus price forecast:
Stock Quotes AnaptysBio Inc.|ANAB - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization AnaptysBio Inc.|ANAB - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share AnaptysBio|ANAB - Book Capitalization|Market Capitalization to Book Value anaptysbio.com|ANAB - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio AnaptysBio, Inc.|ANAB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio AnaptysBio Inc|ANAB - Company Total Debt|Debts to Book Capitalization AnaptysBio Inc.|ANAB - Company Long-Term Debt|Company Short-Term Indebtedness AnaptysBio|Immediate Liquidity anaptysbio.com
- net income and valuation multiples indicators:
ANAB - Net Profit
Summary company analysis:AnaptysBio, Inc.
Core merchandise of AnaptysBio Corp

Profit reflects the net financial result after deducting all operating and non-operating expenses. This indicator measures capital management efficiency and the business's ability to generate value. By analyzing the profit history of the company, an investor can assess the sustainability of cash flows. For AnaptysBio, Inc. (ANAB), this metric depends directly on royalties from antibody licensing. Diversification of development allows for the smoothing of revenue volatility shown on this chart.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|PHAR - Net Profit|Nektar Therapeutics (NKTR) - Company Net Income|Company Profit UPB|ZBIO (Zenas Biopharma) - Net Profit|Net Profit Immunome Inc|Company Net Income Gossamer Corp (GOSS)|KALV: Profit After Tax|Septerna Inc - Net Income|Profit After Payment of Taxes PVLA (pieris.com)|SVRA: Net Income|Company Net Income Rigel Pharma|Astria Pharma (ATXS) - Company Net Income|ENGN - Net Financial Result|RAPT (RAPT Therapeutics, Inc.) - Net Profit|Company Net Income JBIO|Net Profit ACRS|Net Financial Result Kyverna Therapeutics Inc.|Company Net Income Tiziana Life Sciences PLC TLSA|Cabaletta Bio Inc (CABA) - Company Net Income|VTYX: Net Income|Final Profit THTX (theratech.com)|AVTX: Net Profit|ELDN - Net Financial Result|Company Net Income Agenus Inc|Company Profit CLYM (Climb Bio, Inc)|Net Profit ZURA|Net Income atyrpharma.com ATYR|Adagene Inc. - Net Income|Net Financial Result ImageneBio (IMA)|Shattuck Therapeutics - Net Profit|EQ - Net Profit|connectbiopharm.com (CNTB) - Company Net Income|Company Profit IMUX|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|Net Profit InflaRx GmbH|Net Profit XFOR|Company Net Income ACET (adicetbio.com)|Company Net Income Celularity CELU|INMB (inmunebio.com) - Profit After Tax|Barinthus Biotherapeutics plc - Net Profit|Final Profit KZR (Kezar Life Sciences Inc.)|SABS: Net Profit|Akari Therapeutics, Plc (AKTX) - Net Profit|Company Net Income Enlivex Therapeutics Ltd|QTTB: Final Profit|Company Net Income GeoVax (GOVX)|Net Income Edesa Biotech Inc EDSA|Net Profit IBIO (iBio Corp)|Net Profit Carisma Therapeutics Inc CARM|XTLB: Net Income|Final Profit BOLT (Bolt Biotherapeutics)|HCWB: Net Profit|APVO - Net Financial Result|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Company Net Income GRI Bio, Inc. (GRI)|Net Income xortx.com XRTX|Vyome Holdings - Net Income|Net Profit Revelation Biosciences Inc REVB|INDP - Company Net Income|SCNI (BiondVax Pharmaceuticals) - Company Profit|CALI: Net Profit|Company Net Income Affimed N.V. (AFMD)|ALLK (Allakos Inc) - Net Profit|Net Profit HOOKIPA|Company Net Income IGM Biosciences, Inc. (IGMS)|iTeos Pharma - Company Profit|Net Profit OCEA (Ocean Biomedical, Inc.)|Net Profit tcbiopharm.com TCBP|THRD - Company Net Income